1 / 21

Treatment of Visceral Leishmaniasis HIV-Related Dr. Fernando Laguna Hospital Carlos III Madrid

Treatment of Visceral Leishmaniasis HIV-Related Dr. Fernando Laguna Hospital Carlos III Madrid. TREATMENT OF VISCERAL LEISHMANIASIS HIV-RELATED. Which drug?. Length?. Dose?. PATIENTS and METHODS (I). Inclusion/Exclusion. Randomization. Treatment B. Treatment A. Parasitological cure

takara
Télécharger la présentation

Treatment of Visceral Leishmaniasis HIV-Related Dr. Fernando Laguna Hospital Carlos III Madrid

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment of Visceral Leishmaniasis HIV-Related Dr. Fernando Laguna Hospital Carlos III Madrid

  2. TREATMENT OF VISCERAL LEISHMANIASIS HIV-RELATED Which drug? Length? Dose?

  3. PATIENTS and METHODS (I) Inclusion/Exclusion Randomization Treatment B Treatment A Parasitological cure Toxicity Relapses

  4. PATIENTS and METHODS (II) Design:multicentre, open-label with blinded centralised randomisation, parallel, active-controlled clinical trial. Setting: Tertiary Hospitals in Spain. Exclusion criteria: Study Population: • HIV-infected patients with a first episode of VL • >18 years old. • Pancreatitis. • Protrombin activity <40%. • Aminotransferase>10 times. • Creatinin >2 times. • Miocardiopathy... • Allergy... • Pregnant woman...

  5. PATIENTS and METHODS (III) • Endpoint: • Treatment was considered successful if no parasites were detected in a bone marrow aspirate performed 1 month after the end of therapy. • Statistical analysis: • The primary analysis was performed following an intention-to-treat principle.

  6. BACKGROUND • We unknewn the efficacy and safety of pentavalent antimonials. • Amphotericin B was useful in immunocompetent patients with VL and it is very potent in vitro

  7. AIM To compare the efficacy and safety of pentavalent antimonials with amphotericin B in HIV-infected patients with VL.

  8. TREATMENT • Amphotericin B 0,7 mg/kg/d, 28 days • Meglumine antimoniate 20 mg Sbv/kg/d, 28 days

  9. =19 RESULTS (I): Baseline data MA AmB n=45 Age 31 32 90 80 Gender (M, %) CD-4 T cells count 29 (1 - 203) 18 (0 - 231) Risk practice for HIV (%) Previous AIDS (%) n=44 70 67 23 13 IVDU Homo/Bisexual men 64 62

  10. =19 RESULTS (II) : Outcome MA AmB n=45 n=44 Uncompleted treatment 10 15 Toxicity5 5 Death5 5 AbandonedTreatment0 5 Completed Treatment34 30 Cured29 (66%) 28 (62%) Notcured4 2 Losttofollow-up1 0

  11. =19 RESULTS (IV): Toxicity MA AmB n=45 n=44 Pts. with at least one AE(%) 25(55) 27(60) Pts. With suspension of Treatment due to an AE 5(11) 5(11) Cardiotoxicity 6(14) 0 Hyperamylasemia 13(20) 0 Nephrotoxicity 2(5) 16(36)

  12. CONCLUSIONS • Amphotericin B presents a similar efficacy than meglumine antimoniate administered for 28 days. • Treatment-related adverse events leading to therapy discontinuation were similar in both groups.

  13. BACKGROUND Amphotericin B lipid complex, an amphotericin B lipid formulation, is very effective in immunocompetent Indian patients with visceral leishmaniasis

  14. AIM To compare the efficacy and safety of amphotericin B lipid complex (ABLC) versus meglumine antimoniate in HIV-infected patients with a first episode of VL.

  15. PATIENTS and METHODS (I) • Treatment groups: • ABLC 3 mg/kg/d for 5 days (ABLC-5). • ABLC 3 mg/kg/d for 10 days (ABLC-10). • Meglumine antimoniate 20 mg Sbv/kg/d for 28 days (MA-28).

  16. RESULTS (I): Baseline data MA-28 ABLC-5 ABLC-10 n=20 n=19 n=18 Age 34.0 ± 5.2 34.1 ± 6.0 33.7 ± 5.8 16/3 15/3 Gender (M/F) 17/3 CD-4 T cells count 76 ± 142 75 ± 90 110 ± 175 CD-4 T cells <200 / >200 17 / 2 16 / 2 17 / 3 Nº of patients under HAART theraphy 7 5 3 HIV stage (n): A B C 1 2 16 3 5 10 2 5 13

  17. =19 RESULTS (II): Outcome MA ABLC-5 ABLC-10 n=19 n=18 n=20 1 1 17 6 (33%) 10 1 9 5 3 1 10 7 (37%) 2 1 Not confirmed VL No efficacy assessment Toxicity Death Lost follow-up Efficacy assessment Cured Not cured Major P. Violation 1* 2 1* 1 18 8 (42%) 10

  18. RESULTS (III): EFFICACY - ITT population

  19. =19 RESULTS (II): Adverse Events Treatment Related MA ABLC-5 ABLC-10 7 1 1 1 1 8 1 2 3 Death Infusion-related AEs Phlebitis Vomiting Pancreatitis Hyperamilasemia Kidney failure Anemia worsening 1 0 4 4 2 1

  20. CONCLUSION • Amphotericin B lipid complex for 5 or 10 days presents a similar efficacy than meglumine antimoniate administered for 28 days, with a lower frequency of adverse events and a better tolerability. • Treatment related adverse events leading to discontinuation were more frequent in antimonial group than in ABLC groups.

  21. Investigators (alphabetic order): • Dr. J. Altés H. de l´Alt Penedés, Barcelona. • Dr. J. Alvar y C. Cañavate C. Nacional de Microbiología, Majadahonda. • Dr. JR. Arribas y E. Torres H La Paz, Madrid. • Dr. V.Boix H. General, Alicante. • Dr. JM. Gatell y JM. Miró H. Clínic, Barcelona. • Dr. J. Gómez Rodrigo H. Severo Ochoa, Leganés. • Dr.M Górgolas F. Jiménez Díaz, Madrid. • Dr. F. Laguna y P.Martínez H. Carlos III, Madrid. • Dr. R. López-Vélez y JA. Pérez Molina H. Ramón y Cajal, Madrid. • Dr. M. Marquez H. Virgen de la Victoria, Málaga. • Dr. FJ. Medrano y ME. Jiménez Mejías H. Virgen del Rocío, Sevilla. • Dr. J. Pasquau H. Virgen de las Nieves,Granada. • Dr. F. Pulido y R. Rubio H. 12 de Octubre, Madrid. • Dra. G. Picó H. Can Misses, Ibiza. • Dr. E.Ribera y C. Azuaje H. Vall d´Hebron, Barcelona. • Dra. A. Salas H. Son Dureta, Palma. • Dr. J. Sanz H. de la Princesa, Madrid. • Dr. G. Sirera y B.Clotet H. German Trias I Pujol, Badalona. • Dr. J. Torre-Cisneros y JM. Kindelán H. Reina Sofía, Córdoba. • Dr. S.Videla y M.Sust L. Pensa-Esteve, Barcelona.

More Related